NCT03348059View on ClinicalTrials.gov

Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

CompletedOBSERVATIONAL

Enrollment

103

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

March 31, 2017

Conditions

Chronic Hepatitis c

Interventions

DRUG

Direct-acting antiviral therapy

HCV patients received direct-acting antiviral treatment for 12 or 24 weeks

Trial Locations (1)

69004

Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT03348059 - Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy | Biotech Hunter | Biotech Hunter